DEINOVE CREATES A SUBSIDIARY FOR ITS ANTIBIOTICS PROGRAM
- To accelerate research and development of new antibiotics
- With a dedicated management team led by Alain CHEVALLIER and Dominique LE BELLER
- DEINOVE owns 49% of new entity, DEINOBIOTICS SAS, and holds the right to buy back the outstanding shares
Paris March 21 2013 - DEINOVE (Alternext Paris: ALDEI), the Deinococcus bacteria company, announced that the Board of Directors has decided to accelerate the development of the company's antibiotics program by establishing a dedicated subsidiary, DEINOBIOTICS, that incorporates the expertise and resources to meet its ambitions in this field.